Top Markets
#1 Palladium Network Palladium Network +27.90%
#2 Ankr Network Ankr Network +20.08%
#3 Fake World Assets Fake World Assets +8.58%
#4 Status Status +8.22%
#5 Pons Pons +6.97%
#6 Ribbita by Virtuals Ribbita by Virtuals +6.85%
#7 would would +6.62%
#8 WAX WAX +6.52%
#9 edgeX edgeX +6.10%
#10 Hive Hive +4.94%
Coin of the day
Palladium Network Palladium Network
Settings
Language
ENGLISH
Currency
USD
Theme
Acepodia, Inc. Acepodia, Inc.

Acepodia, Inc.

6976
Rank in Stocks #17936
Acepodia, Inc. is an advanced-stage biotechnology firm focused on pioneering... Acepodia, Inc. is an advanced-stage biotechnology firm focused on pioneering cell-based treatments. The company utilizes its distinctive Antibody Cell Conjugation (ACC) platform technology to innovate therapeutic approaches and address critical unmet needs in oncology. Through this proprietary method, Acepodia engineers novel ACE therapies by precisely attaching tumor-specific antibodies to its specialized immune cells, such as gamma delta 2 T cells. Established in 2017, the company's corporate headquarters are situated in Grand Cayman, Cayman Islands.
Share Price
$0.37840843
Last synced: 2026-09-02
Market Cap
$219.66M
Change (1 day)
-0.42%
Change (1 year)
-27.31%
Country
KY
Trade Acepodia, Inc. (6976)

Category

Healthcare
Revenue for Acepodia, Inc. (6976)
Revenue in Sep 2026 TTM: 0
According to Acepodia, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Acepodia, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH